Department of Biotechnology, Government of India
🇮🇳India
- Country
- 🇮🇳India
- Ownership
- Private
- Established
- 1986-01-01
- Employees
- 101
- Market Cap
- -
- Website
- https://dbtindia.gov.in
VeGen Labs Receives ₹3.765 Crore BIRAC Grant to Advance Novel KRAS Inhibitor for Lung Cancer Treatment
• VeGen Labs secures ₹3.765 crore funding from BIRAC to conduct IND-enabling toxicology studies for IND126, a novel KRAS inhibitor targeting Non-Small Cell Lung Cancer treatment.
• As India's first biotech company developing a KRAS inhibitor, VeGen Labs aims to address the critical need in lung cancer treatment, with over 70,000 new cases reported annually in India.
• The BIRAC funding will accelerate the development of IND126 through comprehensive toxicology assessments, positioning the company for first-in-human clinical trials.
© Copyright 2025. All Rights Reserved by MedPath